GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Glaukos Corp (NYSE:GKOS) » Definitions » Cash Flow from Investing

GKOS (Glaukos) Cash Flow from Investing : $47.8 Mil (TTM As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Glaukos Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2024, Glaukos spent $1.7 Mil on purchasing property, plant, equipment. It gained $0.0 Mil from selling property, plant, and equipment. It spent $0.0 Mil on purchasing business. It gained $0.0 Mil from selling business. It spent $66.8 Mil on purchasing investments. It gained $80.3 Mil from selling investments. It paid $0.0Mil for net Intangibles purchase and sale. And it paid $0.0 Mil for other investing activities. In all, Glaukos gained $11.8 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2024.


Glaukos Cash Flow from Investing Historical Data

The historical data trend for Glaukos's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Glaukos Cash Flow from Investing Chart

Glaukos Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -205.06 -58.23 44.78 14.10 47.83

Glaukos Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.92 -29.38 34.86 30.56 11.79

Glaukos Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Glaukos's Cash Flow from Investing for the fiscal year that ended in Dec. 2024 is calculated as:

Glaukos's Cash Flow from Investing for the quarter that ended in Dec. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $47.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Glaukos  (NYSE:GKOS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Glaukos's purchase of property, plant, equipment for the three months ended in Dec. 2024 was $-1.7 Mil. It means Glaukos spent $1.7 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Glaukos's sale of property, plant, equipment for the three months ended in Dec. 2024 was $0.0 Mil. It means Glaukos gained $0.0 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Glaukos's purchase of business for the three months ended in Dec. 2024 was $0.0 Mil. It means Glaukos spent $0.0 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Glaukos's sale of business for the three months ended in Dec. 2024 was $0.0 Mil. It means Glaukos gained $0.0 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Glaukos's purchase of investment for the three months ended in Dec. 2024 was $-66.8 Mil. It means Glaukos spent {stock_data.stock.currency_symbol}}66.8 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Glaukos's sale of investment for the three months ended in Dec. 2024 was $80.3 Mil. It means Glaukos gained $80.3 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Glaukos's net Intangibles purchase and sale for the three months ended in Dec. 2024 was $0.0 Mil. It means Glaukos paid $0.0 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Glaukos's cash from discontinued investing activities for the three months ended in Dec. 2024 was 0.0 Mil. It means Glaukos paid $0.0 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Glaukos's cash from other investing activities for the three months ended in Dec. 2024 was $-0.0 Mil. It means Glaukos paid $0.0 Mil for other investing activities.


Glaukos Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Glaukos's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Glaukos Business Description

Traded in Other Exchanges
Address
One Glaukos Way, Aliso Viejo, CA, USA, 92656
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Executives
Mark J Foley director ZELTIQ AESTHETICS INC., 4698 WILLOW ROAD SUITE 100, PLEASANTON CA 94588
Tomas Navratil officer: Chief Development Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Gilbert H Kliman director C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Joseph E Gilliam officer: CFO, SVP Corporate Development C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92677
Marc Stapley director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
Aimee S Weisner director ONE EDWARDS WAY, IRVINE CA 92614
Alex R. Thurman officer: SVP & Chief Financial Officer C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Thomas William Burns director, 10 percent owner, officer: Chief Executive Officer C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938
Leana Wen director C/O GLAUKOS CORPORATION, 229 AVENIDA FABRICANTE, SAN CLEMENTE CA 92672
Chris M. Calcaterra officer: Chief Commercial Officer C/O GLAUKOS CORPORATION, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Orbimed Advisors Llc director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Jonathan Silverstein director 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Richard L Harrison officer: Treasurer, CFO & Secretary 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653